Table 3.

Clinical trials using DCs in autoimmune disease therapy.

Autoimmune disease	DCreg cell therapy	Stage of study	Patient No.	Status	Refs./Study ID
T1D	tolDCs targeting CD80, CD86, CD40	Phase I	10 participants	Completed	NCT00445913
T1D	tolDCs targeting CD80, CD86, CD40	Phase II	24 participants	Not yet recruiting	NCT02354911
T1D	tolDCs and Proinsuline-loaded VitD3-tolDCs	Phase I	10 participants	Safe and well tolerated and upregulation of B220+ CD11c− B-cell population	NTR5542
T1D	Autologous DCs (AVT001)	Phase I and II	24 participants	Active, not recruiting	NCT03895996
RA	tolDC-Dex-VitD3 loaded with autologous synovial fluid	Phase I	15 participants	Unknown	NCT01352858
RA	Dex-tolDCs	Phase I	10 participants	Completed	NCT03337165
RA	Generated DCreg cells by treating with BAY 11-7082 (Rheumavax)	Phase I	18 patients	Well tolerated, decreased in Teff cells and upregulation of Treg cells	(270)
MS	Generated Dex-tolDCs loaded with aquaporine-4-or myelin-derived peptides	Phase I	20 participants	Completed,	NCT02283671
MS	VitD3-tolDCs loaded with a pool of myelin peptides	Phase I and II	9 participants	Active, not recruiting	NCT02618902
MS	VitD3-tolDCs loaded with a pool of myelin peptides	Phase I and II	16 participants	Recruiting	NCT02903537
CD	Dex/VitA tolDCs	Phase I	–	–	2007-003469-42
CD	Dex-tolDCs	Phase I	3 participants	Terminated (low recruitment)	NCT02622763

tolDC, tolerogenic dendritic cell; Vit D3, vitamin D3; DCreg cell, regulatory dendritic cell; Dex, dexamethasone.